

SECOND AMENDMENT AFTER FINAL  
U.S. Appln. No. 10/664,859

IN THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-60. (Cancelled).

Claim 61. (Currently Amended) An isolated polypeptide ~~comprising~~ consisting of:

(i) a Drosophila Legless (dLgs) protein consisting of amino acid ~~acids~~ 1 to 1464 of SEQ ID NO:23, or

~~(ii) a polypeptide having at least 90% amino acid sequence identity to said (i), wherein said polypeptide inhibits tcf-driven luciferase activity in colon cancer cells, or~~

~~(iii)~~ (ii) a peptide fragment of (i) or (ii), wherein said fragment has the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 and inhibits tcf-driven luciferase activity in colon cancer cells, or

~~(iv)~~ (iii) a peptide fragment of (i) having at least 90% amino acid sequence identity in the evolutionary conserved domain of said (i), wherein said domain to the amino acid sequence of SEQ ID NO:4 and inhibits tcf-driven luciferase activity in colon cancer cells

~~Xaa Xaa Val Phe Ser Thr Xaa Xaa Ala Asn Lys Xaa Ala Glu Xaa Val Leu Xaa Gly Gln Xaa Xaa Thr Ile Xaa Xaa Xaa His (SEQ ID NO:24), or~~

SECOND AMENDMENT AFTER FINAL  
U.S. Appln. No. 10/664,859

~~(v)~~(iv) a peptide having at least 90% amino acid sequence identity ~~in the evolutionary conserved domain of said (i)~~, wherein said domain to the amino acid sequence of SEQ ID NO:5 and inhibits tcf-driven luciferase activity in colon cancer cells~~is~~

~~Xaa Xaa Leu Xaa Xaa Xaa Gln Xaa Xaa His Arg Glu Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Phe Pro Xaa Xaa Xaa Xaa Xaa Xaa Gly Ala (SEQ ID NO:25), or~~

(v) a peptide fragment of (i) having at least 90% amino acid sequence identity to the amino acid sequence of SEQ ID NO:2 and inhibits tcf-driven luciferase activity in colon cancer cells, or

(vi) a peptide fragment of (i) having at least 90% amino acid sequence identity to the amino acid sequence of SEQ ID NO:3 and inhibits tcf-driven luciferase activity in colon cancer cells.

Claims 62-63. (Cancelled).

Claim 64. (Previously Presented) A chimeric molecule comprising the polypeptide of Claim 61 fused to a heterologous polypeptide.

Claim 65. (Previously Presented) The chimeric molecule according to Claim 64, wherein said heterologous polypeptide is selected from the group consisting of an antigenic epitope, glutathione-S-transferase, thioredoxin, and antibody.

Claim 66. (Previously Presented) A pharmaceutical composition comprising the polypeptide of Claim 61, and a pharmaceutically acceptable carrier.

**SECOND AMENDMENT AFTER FINAL**  
**U.S. Appln. No. 10/664,859**

Claim 67. (New) An isolated polypeptide comprising a Drosophila Legless (dLgs) protein comprising amino acids 1 to 1464 of SEQ ID NO:23.

Claim 68. (New) The isolated protein as claimed in Claim 67, wherein said protein is encoded by a nucleotide molecule having the nucleotide sequence of SEQ ID NO:1.

Claim 69. (New) A chimeric molecule comprising the polypeptide of Claim 67 fused to a heterologous polypeptide.

Claim 70. (New) The chimeric molecule according to Claim 69, wherein said heterologous polypeptide is selected from the group consisting of an antigenic epitope, glutathione-S-transferase, thioredoxin, and antibody.

Claim 71. (New) A pharmaceutical composition comprising the polypeptide of Claim 67, and a pharmaceutically acceptable carrier.